TRAP1 Activators

TRAP1, a mitochondrial chaperone protein, is intricately involved in maintaining mitochondrial integrity and function, particularly under stress conditions. Its activators, through various mechanisms, primarily enhance its activity by inducing mitochondrial stress or affecting related chaperone proteins. Geldanamycin, 17-AAG, and Radicicol target Hsp90, a chaperone closely associated with TRAP1. The inhibition of Hsp90 by these compounds leads to an indirect upregulation of TRAP1, thereby enhancing its chaperone activity within mitochondria. This is crucial for maintaining protein folding and protecting against mitochondrial stress. Similarly, compounds like Zoledronic Acid, Chloroquine, and Doxorubicin induce mitochondrial stress through different pathways, ranging from bisphosphonate action to antimalarial effects. This stress, in turn, enhances the activity of TRAP1 as it acts to mitigate mitochondrial dysfunction and protect against stress-induced damage.

Further extending this paradigm, compounds like Ritonavir, MG-132, and Staurosporine also promote TRAP1 activity by inducing mitochondrial stress. Ritonavir, as an antiretroviral drug, and MG-132, a proteasome inhibitor, lead to cellular and mitochondrial stress, requiring TRAP1's protective action. Staurosporine, a kinase inhibitor, similarly induces mitochondrial stress, which TRAP1 counters by protecting mitochondrial proteins and maintaining mitochondrial integrity. Phenformin and Metformin, both antidiabetic drugs, enhance TRAP1 activity by inhibiting complex I of the electron transport chain, leading to mitochondrial stress. This stress necessitates an increased activity of TRAP1 to maintain mitochondrial function. Lastly, Tunicamycin induces ER stress, which can extend to affect mitochondria, thereby enhancing the activity of TRAP1 as it ensures protein integrity and mitigates stress responses within the mitochondria.